How many insider trades does FilingIQ track for TARS?

FilingIQ tracks 395 Form 4 insider transactions for TARS (Tarsus Pharmaceuticals, Inc.), covering filings from Oct 20, 2020 onwards. 74 of those were filed in the last 90 days.

Are TARS insiders net buyers or net sellers?

Across the full Form 4 history for TARS, 11 transactions (3%) were open-market purchases and 240 (61%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TARS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TARS in?

Tarsus Pharmaceuticals, Inc. (TARS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.83B.

TARS insider trading

NasdaqGS Healthcare

Tarsus Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

395

Last 90 days

Buys / sells

3% / 61%

Market cap

$2.83B

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Company website: www.tarsusrx.com

TARS insider activity at a glance

FilingIQ has scored 395 insider transactions for TARS since Oct 20, 2020. The most recent filing in our index is dated Apr 24, 2026.

Across the full history, 11 open-market purchases and 240 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TARS insider trades is 58.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TARS trades on FilingIQ Raw filings on SEC EDGAR

Latest TARS Form 4 filings

Azamian Bobak R. President/CEO and Board Chair

S Mar 19, 2026

Azamian Bobak R. President/CEO and Board Chair

S Mar 18, 2024

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading TARS

Azamian Bobak R.

13 trades · score 73.7

13F funds holding TARS

COWEN AND COMPANY, LLC

$38.71M · 2.5% of AUM

Frazier Life Sciences Management, L.P.

$26.21M · 1.6% of AUM

Ikarian Capital, LLC

$25.82M · 2.8% of AUM

TFG Asset Management GP Ltd

$11.07M · 2.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for TARS?: FilingIQ tracks 395 Form 4 insider transactions for TARS (Tarsus Pharmaceuticals, Inc.), covering filings from Oct 20, 2020 onwards. 74 of those were filed in the last 90 days.
Are TARS insiders net buyers or net sellers?: Across the full Form 4 history for TARS, 11 transactions (3%) were open-market purchases and 240 (61%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TARS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TARS in?: Tarsus Pharmaceuticals, Inc. (TARS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.83B.

Methodology & sources

Every TARS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.